Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory
conditions have highlighted the significant benefit to patients who respond to MSC …

Background Despite increased interest in mesenchymal stromal cell (MSC)-based cell
therapies for acute respiratory distress syndrome (ARDS), clinical investigations have not yet …

Recent advances in cell based therapies for lung diseases and critical illnesses offer
significant promise. Despite encouraging preclinical results, the translation of efficacy to the …

Acute respiratory distress syndrome (ARDS) causes respiratory failure, which is associated
with severe inflammation and lung damage and has a high mortality and for which there is …

Mesenchymal stem/stromal cells (MSCs) have become the focus of intense research effort
over the past 10 years, in an effort to harness their regenerative and immune-modulating …

Abstract Purpose of Review Mesenchymal stromal cell (MSC)–based therapies provide a
platform for new therapeutic strategies in lung diseases. This review provides an overview of …

Mesenchymal stromal cells (MSCs) were identified more than 50 years ago, and research
advances have promoted the translation of pre-clinical studies into clinical settings in …

There is considerable interest in the potential for cell-based therapies, particularly
mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory …

Mesenchymal stromal cells (MSCs) have been investigated as a treatment for various
inflammatory diseases because of their immunomodulatory and reparative properties …

The acute respiratory distress syndrome (ARDS) is a multifaceted lung disorder in which no
specific therapeutic intervention is able to effectively improve clinical outcomes. Despite an …